TY - JOUR
T1 - Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy
T2 - a case report
AU - D’Alessandris, Quintino Giorgio
AU - Montano, Nicola
AU - Martini, Maurizio
AU - Cenci, Tonia
AU - Lauretti, Liverana
AU - Stumpo, Vittorio
AU - Pignotti, Fabrizio
AU - Olivi, Alessandro
AU - Fernandez, Eduardo
AU - Larocca, Luigi Maria
AU - Pallini, Roberto
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Treatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor—namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA—and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma.
AB - Treatment options for recurrent glioblastoma are scarce; targeted therapy trials were disappointing, probably due to enrollment of patients without molecular selection. We treated with bevacizumab and erlotinib a 66-year-old male suffering from recurrent glioblastoma, IDH-wildtype and MGMT unmethylated, after three neurosurgeries. Treatment was tailored on molecular profile of recurrent tumor—namely, EGFRvIII positivity, VEGF overexpression, normal PTEN, low total VEGF and VEGF-121 mRNA—and resulted in complete, exceptionally durable response (51-month progression-free survival). Notably, histology of further recurrence after therapy was reminiscent of sarcoma. We suggest a thorough molecular screening for personalization of targeted therapy in recurrent glioblastoma.
KW - Bevacizumab
KW - Erlotinib
KW - Glioblastoma
KW - Tailored therapy
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85055184229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055184229&partnerID=8YFLogxK
U2 - 10.1007/s00701-018-3697-3
DO - 10.1007/s00701-018-3697-3
M3 - Article
C2 - 30306271
AN - SCOPUS:85055184229
SN - 0001-6268
JO - Acta Neurochirurgica
JF - Acta Neurochirurgica
ER -